Expedition Therapeutics raises $115.0M Series B (United States, Aug 2026)
Reach the investors backing rounds like this
Backed by General Atlantic, RA Capital +6 more · verified emails and LinkedIn on Datapile
Expedition secures $115 million to tackle COPD inflammation - Longevity.Technology
Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for chronic obstructive pulmonary disease (COPD). The company is notable for its lead therapy, EXPD-101, which targets inflammation in the lungs, aiming to intervene earlier in the disease process rather than just alleviating symptoms. The recent $115 million Series B financing will support the launch of a global Phase 2 clinical trial for this treatment.
Expedition secures $115 million to tackle COPD inflammation Longevity.Technology
20,207 investors back startups in United States
You just read who funded Expedition Therapeutics. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.